Polygenic susceptibility to breast cancer: Current state-of-the-art

Future Oncology

Volumn 5, Issue 5, 2009, Pages 689-701

  Ghoussaini, Maya ^a   Pharoah, Paul D P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Association studies; Breast cancer; Clinical relevance; Frequent variants; Genetic susceptibility; Genome wide association; Low penetrance; Risk prediction

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FLICE INHIBITORY PROTEIN; MYC PROTEIN;

AGE DISTRIBUTION; BREAST CANCER; CANCER INVASION; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENE OVEREXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; LIFESTYLE; MULTIFACTORIAL INHERITANCE; PATHOGENESIS; PENETRANCE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; BREAST TUMOR; FEMALE; GENETIC PREDISPOSITION; GENETICS; RISK FACTOR;

BREAST NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MULTIFACTORIAL INHERITANCE; RISK FACTORS;

EID: 69849107956     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.29     Document Type: Review

References (91)

1. Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 24(14), 2137-2150 (2006).
2. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH: Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J. Natl Cancer Inst. 86(21), 1600-1608 (1994).
3. Hemminki K, Vaittinen P: Familial breast cancer in the family-cancer database. Int. J. Cancer 77(3), 386-391 (1998).
4. Lichtenstein P, Holm NV, Verkasalo PK et al.: Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N. Engl. J. Med. 343(2), 78-85 (2000).
5. Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer. Nat. Genet. 26(4), 411-414 (2000).
6. Hall JM, Lee MK, Newman B et al.: Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988), 1684-1689 (1990).
7. Miki Y, Swensen J, Shattuck-Eidens D et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182), 66-71 (1994).
8. Wooster R, Neuhausen SL, Mangion J et al.: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265(5181), 2088-2090 (1994).
9. Wooster R, Bignell G, Lancaster J et al.: Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559), 789-792 (1995).
10. Antoniou A, Pharoah PD, Narod S et al.: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72(5), 1117-1130 (2003).
11. Malkin D, Li FP, Strong LC et al.: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250(4985), 1233-1238 (1990).
12. Nelen MR, Padberg GW, Peeters EA et al.: Localization of the gene for Cowden disease to chromosome 10q22-23. Nat. Genet. 13(1), 114-116 (1996).
13. Nelen MR, van Staveren WC, Peeters EA et al.: Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum. Mol. Genet. 6(8), 1383-1387 (1997).
14. Waite KA, Eng C: Protean PTEN: form and function. Am. J. Hum. Genet. 70(4), 829-844 (2002).
15. Antoniou AC, Hardy R, Walker L et al.: Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J. Med. Genet. 45(7), 425-431 (2008).
16. Easton DF: Cancer risks in A-T heterozygotes. Int. J. Radiat. Biol. 66(Suppl. 6), S177-S182 (1994).
17. Renwick A, Thompson D, Seal S et al.: ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat. Genet. 38(8), 873-875 (2006).
18. Savitsky K, Bar-Shira A, Gilad S et al.: A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268(5218), 1749-1753 (1995).
19. Seal S, Thompson D, Renwick A et al.: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat. Genet. 38(11), 1239-1241 (2006).
20. Bell DW, Varley JM, Szydlo TE et al.: Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 286(5449), 2528-2531 (1999).
21. Meijers-Heijboer H, van den Ouweland A, Klijn J et al.: Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat. Genet. 31(1), 55-59 (2002).
22. Erkko H, Dowty JG, Nikkila J et al.: Penetrance analysis of the PALB2 c.1592delT founder mutation. Clin. Cancer Res. 14(14), 4667-4671 (2008).
23. Rahman N, Seal S, Thompson D et al.: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 39(2), 165-167 (2007).
24. Smith P, McGuffog L, Easton DF et al.: A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer 45(7), 646-655 (2006).
25. Easton DF: How many more breast cancer predisposition genes are there? Breast Cancer Res. 1(1), 14-17 (1999).
26. Cox A, Dunning AM, Garcia-Closas M et al.: A common coding variant in CASP8 is associated with breast cancer risk. Nat. Genet. 39(3), 352-358 (2007).
27. Easton DF, Pooley KA, Dunning AM et al.: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447(7148), 1087-1093 (2007).
28. Gold B, Kirchhoff T, Stefanov S et al.: Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc. Natl Acad. Sci. USA 105(11), 4340-4345 (2008).
29. Hunter DJ, Kraft P, Jacobs KB et al.: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet. 39(7), 870-874 (2007).
30. Stacey SN, Manolescu A, Sulem P et al.: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 39(7), 865-869 (2007).
31. Stacey SN, Manolescu A, Sulem P et al.: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet. 40(6), 703-706 (2008).
32. Ahmed S, Thomas G, and Ghoussaini M et al.: Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat. Genet. 41(5), 585-590 (2009).
33. Zheng W, Long J, Gao YT et al.: Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat. Genet. 41(3), 324-328 (2009).
34. Garcia-Closas M, Malats N, Silverman D et al.: NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 366(9486), 649-659 (2005).
35. Barnhart BC, Lee JC, Alappat EC, Peter ME: The death effector domain protein family. Oncogene 22(53), 8634-8644 (2003).
36. Fulda S: Caspase-8 in cancer biology and therapy. Cancer Lett. (2008) (Epub ahead of print).
37. Saunier EF, Akhurst RJ: TGF β inhibition for cancer therapy. Curr. Cancer Drug Targets 6(7), 565-578 (2006).
38. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA: Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31(1), 33-36 (2002).
39. Pharoah PD, Tyrer J, Dunning AM, Easton DF, Ponder BA: Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet. 3(3), e42 (2007).
40. Altshuler D, Daly MJ, Lander ES: Genetic mapping in human disease. Science 322(5903), 881-888 (2008).
41. Yang Q, Cui J, Chazaro I, Cupples LA, Demissie S: Power and type I error rate of false discovery rate approaches in genome-wide association studies. BMC Genet. 6(Suppl. 1), S134 (2005).
42. Pearson TA, Manolio TA: How to interpret a genome-wide association study. JAMA 299(11), 1335-1344 (2008).
43. Pe'er I, Yelensky R, Altshuler D, Daly MJ: Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 32(4), 381-385 (2008).
44. Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 273(5281), 1516-1517 (1996).
45. Waterston RH, Lindblad-Toh K, Birney E et al.: Initial sequencing and comparative ana lysis of the mouse genome. Nature 420(6915), 520-562 (2002).
46. Liang J, Chen P, Hu Z et al.: Genetic variants in ?broblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 29(12), 2341-2346 (2008).
47. Raskin L, Pinchev M, Arad C et al.: FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol. Biomarkers Prev. 17(5), 1060-1065 (2008).
48. Udler MS, Meyer KB, Pooley KA et al.: FGFR2 variants and breast cancer risk: fine-scale mapping using African-American studies and ana lysis of chromatin conformation. Hum. Mol. Genet. 18(9), 1692-1703 (2009).
49. Antoniou AC, Spurdle AB, Sinilnikova OM et al.: Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am. J. Hum. Genet. 82(4), 937-948 (2008).
50. Meyer KB, Maia AT, O'Reilly M et al.: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol. 6(5), e108 (2008).
51. Dickson C, Spencer-Dene B, Dillon C, Fantl V: Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors. Breast Cancer Res. 2(3), 191-196 (2000).
52. Adnane J, Gaudray P, Dionne CA et al.: BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6(4), 659-663 (1991).
53. Jang JH, Shin KH, Park JG: Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers. Cancer Res. 61(9), 3541-3543 (2001).
54. Moffa AB, Tannheimer SL, Ethier SP: Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol. Cancer Res. 2(11), 643-652 (2004).
55. Greenman C, Stephens P, Smith R et al.: Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007).
56. Turnbull C, Rahman N: Genetic predisposition to breast cancer: past, present, and future. Annu. Rev. Genomics Hum. Genet. 9, 321-345 (2008).
57. Luqmani YA, Graham M, Coombes RC: Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues. Br. J. Cancer 66(2), 273-280 (1992).
58. Garcia-Closas M, Hall P, Nevanlinna H et al.: Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet. 4(4), e1000054 (2008).
59. O'Flaherty E, Kaye J: TOX defines a conserved subfamily of HMG-box proteins. BMC Genomics 4(1), 13 (2003).
60. Smid M, Wang Y, Klijn JG et al.: Genes associated with breast cancer metastatic to bone. J. Clin. Oncol. 24(15), 2261-2267 (2006).
61. Dhanasekaran DN, Johnson GL: MAPKs: function, regulation, role in cancer and therapeutic targeting. Oncogene 26(22), 3097-3099 (2007).
62. Easton DF, Eeles RA: Genome-wide association studies in cancer. Hum. Mol. Genet. 17(R2), R109-R115 (2008).
63. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA: Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers. Prostate 11(4), 327-337 (1987).
64. Sears RC: The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3(9), 1133-1137 (2004).
65. Wang YH, Liu S, Zhang G et al.: Knockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo. Breast Cancer Res. 7(2), R220-R228 (2005).
66. Amundadottir LT, Sulem P, Gudmundsson J et al.: A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38(6), 652-658 (2006).
67. Ghoussaini M, Song H, Koessler T et al.: Multiple loci with different cancer specificities within the 8q24 gene desert. J. Natl Cancer Inst. 100(13), 962-966 (2008).
68. Gudmundsson J, Sulem P, Manolescu A et al.: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39(5), 631-637 (2007).
69. Haiman CA, Le ML, Yamamato J et al.: A common genetic risk factor for colorectal and prostate cancer. Nat. Genet. 39(8), 954-956 (2007).
70. Haiman CA, Patterson N, Freedman ML et al.: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat. Genet. 39(5), 638-644 (2007).
71. Kiemeney LA, Thorlacius S, Sulem P et al.: Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40(11), 1307-1312 (2008).
72. Tomlinson I, Webb E, Carvajal-Carmona L et al.: A genome-wide association scan of tag SNPs identi?es a susceptibility variant for colorectal cancer at 8q24.21. Nat. Genet. 39(8), 984-988 (2007).
73. Yeager M, Orr N, Hayes RB et al.: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39(5), 645-649 (2007).
74. Zanke BW, Greenwood CM, Rangrej J et al.: Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24. Nat. Genet. 39(8), 989-994 (2007).
75. Quarmby LM, Mahjoub MR: Caught Nek-ing: cilia and centrioles. J. Cell Sci. 118(Pt 22), 5161-5169 (2005).
76. Chen Y, Choong LY, Lin Q et al.: Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol. Cell Proteomics 6(12), 2072-2087 (2007).
77. Min J, Okada S, Kanzaki M et al.: Synip: a novel insulin-regulated syntaxin 4-binding protein mediating GLUT4 translocation in adipocytes. Mol. Cell 3(6), 751-760 (1999).
78. Cavdar KE, Burkhart W, Blackburn K, Moseley A, Spremulli LL: The small subunit of the mammalian mitochondrial ribosome. Identification of the full complement of ribosomal proteins present. J. Biol. Chem. 276(22), 19363-19374 (2001).
79. Cavdar KE, Ranasinghe A, Burkhart W et al.: A new face on apoptosis: death-associated protein 3 and PDCD9 are mitochondrial ribosomal proteins. FEBS Lett. 492(1-2), 166-170 (2001).
80. Theodorou V, Boer M, Weigelt B, Jonkers J, van der Valk N, Hilkens J: Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 23(36), 6047-6055 (2004).
81. Hashimoto T, Shindo Y, Souri M, Baldwin GS: A new inhibitor of mitochondrial fatty acid oxidation. J. Biochem. 119(6), 1196-1201 (1996).
82. Clemons M, Goss P: Estrogen and the risk of breast cancer. N. Engl. J. Med. 344(4), 276-285 (2001).
83. Key T, Appleby P, Barnes I, Reeves G: Endogenous sex hormones and breast cancer in postmenopausal women: reana lysis of nine prospective studies. J. Natl Cancer Inst. 94(8), 606-616 (2002).
84. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A et al.: A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J. Natl Cancer Inst. 87(3), 190-197 (1995).
85. Holst F, Stahl PR, Ruiz C et al.: Estrogen receptor a (ESR1) gene amplification is frequent in breast cancer. Nat. Genet. 39(5), 655-660 (2007).
86. Gartner CE, Barendregt JJ, Hall WD: Multiple genetic tests for susceptibility to smoking do not outperform simple family history. Addiction 104(1), 118-126 (2009).
87. Janssens AC, van Duijn CM: Genome-based prediction of common diseases: advances and prospects. Hum. Mol. Genet. 17(R2), R166-R173 (2008).
88. Pharoah PD, Antoniou AC, Easton DF, Ponder BA: Polygenes, risk prediction, and targeted prevention of breast cancer. N. Engl. J. Med. 358(26), 2796-2803 (2008).
89. Wray NR, Goddard ME, Visscher PM: Prediction of individual genetic risk of complex disease. Curr. Opin. Genet. Dev. 18(3), 257-263 (2008).
90. Gail MH: Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J. Natl Cancer Inst. 100(14), 1037-1041 (2008).
91. McCarthy MI, Hirschhorn JN: Genome-wide association studies: potential next steps on a genetic journey. Hum. Mol. Genet. 17(R2), R156-R165 (2008).